Insulet Corporation (PODD)

In the past six months, Insulet Corp.'s stock (PODD) reached a 52-week high of $354.88 on November 20, 2025, and a 52-week low of $230.05 on March 10, 2025. As of January 12, 2026, the stock closed at $278.55. Key events impacting the stock include strong Q3 2025 earnings, the Investor Day outlining the long-term strategy for 2025-2028, FDA clearance of Omnipod 5 algorithm enhancements, strong Q1 2025 earnings, and analyst actions such as Barclays downgrading Insulet and Canaccord maintaining a Buy rating. Insulet is scheduled to report its fourth-quarter and full-year 2025 financial results on February 18, 2026.

Information directly detailing demand seasonality for Insulet Corp.'s products and services was not explicitly found in the provided search results. However, the company has consistently reported strong and growing demand for its Omnipod system, driven by factors such as the expansion of Omnipod 5 into new markets, increased adoption among both type 1 and type 2 diabetes patients, and integrations with continuous glucose monitors. The recurring revenue model from the disposable Pods also suggests a relatively stable demand once a customer is onboarded. While no specific seasonal fluctuations were identified, the overall trend indicates robust and sustained demand.

Insulet Corporation is a medical technology company focused on diabetes management. Its core product is the Omnipod System, a tubeless, wearable insulin pump that delivers continuous insulin therapy. The Omnipod platform includes the Omnipod 5 Automated Insulin Delivery (AID) System, which integrates with continuous glucose monitors (CGMs) for automated insulin dosing, controllable via a smartphone app or a dedicated controller. Other products include the Omnipod DASH Insulin Management System and the Omnipod GO pre-filled disposable Pod system for basal insulin users with type 2 diabetes. Insulet also collaborates with biotechnology and pharmaceutical companies to adapt its Pod technology for the delivery of non-insulin subcutaneous drugs in other therapeutic areas.

Insulet Corporation has a significant global presence, serving customers across 25 countries in North America, Europe, the Middle East, and Asia Pacific. The company has manufacturing facilities in the U.S. and Malaysia. Insulet has been actively expanding its international reach, with Omnipod 5 launching in nine new countries since early 2025, bringing its global footprint to 14 markets. International Omnipod revenue has shown impressive growth.

Insulet has cultivated a strong brand reputation, particularly with its Omnipod® System, which is recognized as the #1 most prescribed Automated Insulin Delivery (AID) system in the U.S. in 2024. The company emphasizes a patient-centric approach and empathy-led, science-driven innovation. Insulet launched "The Day Diabetes Showed Up to Work" campaign to raise awareness and provide resources for managing diabetes in the workplace. The FDA clearance of Omnipod 5 algorithm enhancements further solidifies the brand's commitment to innovation and patient benefit. Insulet expanded its Omnipod U.S. recycling program, diverting millions of Pods from landfills and promoting a more sustainable future. Showcasing "Liveable Technology" at CES highlights Insulet's focus on human-centered connected health and innovation.

Insulet Corporation's ownership structure is predominantly held by institutional investors, with institutional ownership near 80%. Top institutional holders include The Vanguard Group, Inc., BlackRock, Inc., FMR LLC (Fidelity Management & Research Co. LLC), Capital Research Global Investors, State Street Corp., Baillie Gifford & Co., Geode Capital Management LLC, ClearBridge Investments, LLC, and American Century Investment Management Inc. Insider ownership is relatively low, with only 0.39% of the stock held by insiders.